Mitsubishi Tanabe Pharma America, Inc. (MTPA), a wholly-owned subsidiary of Jaan-based Mitsubishi Tanabe Pharma Corporation's (MTPC) 100% owned US holding company, Mitsubishi Tanabe Pharma Holdings America, Inc., announced on Thursday that it has completed enrolment for the global, multi-centre, double-blind, Phase 3b study (MT-1186-A02) evaluating the long-term efficacy and safety of two dosing regimens of RADICAVA ORS (edaravone) in people with amyotrophic lateral sclerosis (ALS) over 48 weeks.
This study is the post-marketing commitment following the US Food and Drug Administration (FDA) approval of intravenous (IV) RADICAVA (edaravone). Topline results of the study are anticipated in 2024.
Study MT-1186-A02, which enrolled 384 people with ALS across 80 sites in the US, Canada, Europe and Asia, will compare two dosing regimens for RADICAVA ORS over 48 weeks of treatment. After a screening period of eight weeks, study participants (18 to 75 years of age) will receive RADICAVA ORS either once-daily or following the FDA-approved on/off dosing regimen administered in 28-day cycles. The primary endpoint will measure change in ALS Functional Rating Scale-Revised (ALSFRS-R) score from baseline to week 48 of treatment.
Key secondary endpoints for the study include the change from baseline in percent-predicted slow vital capacity (SVC) and the change from baseline in the ALS Assessment Questionnaire (ALSAQ-40) at 48 weeks, as well as the time to death, tracheostomy or permanent assisted mechanical ventilation. Other secondary endpoints include the change from screening and baseline in percent-predicted forced vital capacity (FVC) at 24 and 48 weeks.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial